The aforementioned data collectively provide a justification for the utility of small-molecule inhibitors of kinases as a therapeutic approach targeting SYK in hematological malignancies, namely in AML [120], DLBCL [124], and in NHL and CLL [125]. This evidence concerns the gene SYK and B-cell chronic lymphocytic leukemia.